TY - JOUR
T1 - Clear cell papillary renal cell carcinoma
T2 - Characteristics and survival outcomes from a large single institutional series
AU - Steward, James E.
AU - Kern, Sean Q.
AU - Cheng, Liang
AU - Boris, Ronald S.
AU - Tong, Yan
AU - Bahler, Clint D.
AU - Masterson, Timothy A.
AU - Cary, K. Clint
AU - Kaimakliotis, Hristos
AU - Gardner, Thomas
AU - Sundaram, Chandru P.
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/6
Y1 - 2021/6
N2 - Objectives: To investigate the clinical characteristics and survival outcomes of a large clear cell papillary renal cell carcinoma cohort. Methods and Materials: A retrospective review of patients with clear cell papillary renal cell carcinoma at a single academic center was performed after Institutional Review Board approval. Patients underwent either partial or radical nephrectomy from September 2009 to July 2019. Demographic and clinical characteristics, recurrence, and cancer specific and overall survival were reported. Results: A total of 90 patients were included in the study. Median follow up was 26.5 months. Median age was 61 (range 27 to 87). 47.8% of patients were African American. 26.7% of patients had end stage renal disease. 37.8% had multifocal renal tumors. 48.9% underwent partial nephrectomy, while the remainder underwent radical nephrectomy. 43.3% underwent an open surgical approach, 40.0% a robotic approach, and 16.7% a laparoscopic approach. Pathologic stage included T1a (90.0%), T1b (1.1%), and T2b (8.9%). Fuhrman grades 1-3 were present in 18.9%, 77.8%, and 3.3% of patients, respectively. There were no cancer specific deaths. There was one local recurrence and no metastases. The overall survival at a median follow up of 26.5 months was 92.1% (95% confidence interval 83.1%–96.4%). Conclusions: Clear cell papillary renal cell carcinoma typically presents at a low stage and grade and has favorable survival outcomes. A nephron-sparing approach to treatment should be considered when feasible due to the tumor's indolent nature and propensity towards multifocality.
AB - Objectives: To investigate the clinical characteristics and survival outcomes of a large clear cell papillary renal cell carcinoma cohort. Methods and Materials: A retrospective review of patients with clear cell papillary renal cell carcinoma at a single academic center was performed after Institutional Review Board approval. Patients underwent either partial or radical nephrectomy from September 2009 to July 2019. Demographic and clinical characteristics, recurrence, and cancer specific and overall survival were reported. Results: A total of 90 patients were included in the study. Median follow up was 26.5 months. Median age was 61 (range 27 to 87). 47.8% of patients were African American. 26.7% of patients had end stage renal disease. 37.8% had multifocal renal tumors. 48.9% underwent partial nephrectomy, while the remainder underwent radical nephrectomy. 43.3% underwent an open surgical approach, 40.0% a robotic approach, and 16.7% a laparoscopic approach. Pathologic stage included T1a (90.0%), T1b (1.1%), and T2b (8.9%). Fuhrman grades 1-3 were present in 18.9%, 77.8%, and 3.3% of patients, respectively. There were no cancer specific deaths. There was one local recurrence and no metastases. The overall survival at a median follow up of 26.5 months was 92.1% (95% confidence interval 83.1%–96.4%). Conclusions: Clear cell papillary renal cell carcinoma typically presents at a low stage and grade and has favorable survival outcomes. A nephron-sparing approach to treatment should be considered when feasible due to the tumor's indolent nature and propensity towards multifocality.
KW - Clear cell
KW - Kidney neoplasms
KW - Nephrectomy
KW - Papillary
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85103012818&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2021.02.003
DO - 10.1016/j.urolonc.2021.02.003
M3 - Article
C2 - 33771410
AN - SCOPUS:85103012818
SN - 1078-1439
VL - 39
SP - 370.e21-370.e25
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 6
ER -